De Bruyn Christine, Baert Thaïs, Van den Bosch Thierry, Coosemans An
Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.
Department of Obstetrics and Gynecology, University Hospital Antwerp, Edegem, Belgium.
Curr Oncol Rep. 2020 Jan 29;22(2):12. doi: 10.1007/s11912-020-0864-5.
Uterine cancer comprises endometrial carcinoma and the uterine sarcoma. Endometrial carcinomas are the most frequent variant and have early symptoms and a solid diagnostic work up, resulting in a rather fair prognosis. However, in case of advanced stage disease and relapse, treatment options are limited and prognosis is impaired. Uterine sarcomas are rare, often lacking symptoms and no diagnostic tool for correct pre-operative diagnosis are available. Prognosis is poor.
Circulating biomarkers as a liquid biopsy could be beneficial as a diagnostic tool in uterine sarcomas. For both carcinomas and sarcomas, circulating biomarkers could be of use in predicting early disease recurrence. This review in endometrial carcinoma and uterine sarcoma focus on circulating biomarkers; such as proteins; circulating tumor cells; circulating tumor DNA; microRNA; and immune cells.
子宫癌包括子宫内膜癌和子宫肉瘤。子宫内膜癌是最常见的类型，有早期症状且诊断检查完善，预后相对较好。然而，对于晚期疾病和复发情况，治疗选择有限且预后不佳。子宫肉瘤罕见，通常缺乏症状，目前尚无用于术前正确诊断的诊断工具，预后较差。
循环生物标志物作为一种液体活检方法，可能有助于子宫肉瘤的诊断。对于子宫内膜癌和子宫肉瘤，循环生物标志物都可用于预测疾病早期复发。本综述聚焦于子宫内膜癌和子宫肉瘤中的循环生物标志物，如蛋白质、循环肿瘤细胞、循环肿瘤DNA、微小RNA和免疫细胞。
